The safety and tolerability profile of etravirine was comparable to placebo, with the exception of rash (17.2, 27.8) (18.7, 29.5). Virologic response rates in both treatment groups increased with increasing number of active agents. The incidence and severity of laboratory abnormalities, including hepatic and lipid parameters, was generally similar between the etravirine and placebo groups. No consistent or clinically relevant trends in laboratory, vital signs or ECG data were observed.

DUET-1 and DUET-2 differ only in geographic location. Patients with viral load <50 copies/mL at Week 48 (%) were imputed as 49 copies/mL; SE= standard error. No relationship with baseline CD4 cell count.